Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prostate-specific antigen.

D K Ornstein1, R S Pruthi

  • 1Department of Surgery/Division of Urology, University of North Carolina at Chapel Hill, 427 Burnett-Womack Building, CB #7235, Chapel Hill, NC 27599-7235, USA. ornstein@med.unc.edu

Expert Opinion on Pharmacotherapy
|March 16, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of clinical and pathological features in African-American and Caucasian patients with localized prostate cancer.

BJU international·2004
Same author

The use of a fibrin tissue sealant during laparoscopic partial nephrectomy.

BJU international·2004
Same author

A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy.

BJU international·2004
Same author

Hand-assisted laparoscopic nephrectomy: complications related to the handport site.

BJU international·2003
Same author

How to improve prostate biopsy detection of prostate cancer.

Current urology reports·2002
Same author

Molecular profiling of clinical tissues specimens: feasibility and applications.

The Journal of molecular diagnostics : JMD·2001
Same journal

Pharmacotherapeutic interventions for pediatric ulcerative colitis.

Expert opinion on pharmacotherapy·2026
Same journal

The rise and fall of TRPV1-targeted analgesia in osteoarthritis: a critical appraisal.

Expert opinion on pharmacotherapy·2026
Same journal

Dopamine transporter and beyond: evolving targets and combination strategies in stimulant use disorder.

Expert opinion on pharmacotherapy·2026
Same journal

GnRH antagonists for the treatment of fibroids and adenomyosis, current evidence and future perspectives.

Expert opinion on pharmacotherapy·2026
Same journal

Pharmacotherapeutic strategies for the management of congenital adrenal hyperplasia.

Expert opinion on pharmacotherapy·2026
Same journal

Current advances in pharmacotherapeutic strategies for the treatment of complicated intra-abdominal infections.

Expert opinion on pharmacotherapy·2026
See all related articles

Serum prostate-specific antigen (PSA) testing aids in early prostate cancer detection and monitoring. Adjusting screening protocols and PSA cut-offs can improve accuracy and reduce unnecessary biopsies, potentially lowering mortality.

Area of Science:

  • Urology
  • Oncology
  • Biomarker Research

Background:

  • Serum prostate-specific antigen (PSA) is a key biomarker for prostate cancer.
  • PSA testing is crucial for early detection, staging, and monitoring treatment efficacy.
  • Current PSA screening protocols and interpretation remain subjects of ongoing debate.

Purpose of the Study:

  • To evaluate the utility of serum PSA measurements in prostate cancer management.
  • To explore strategies for optimizing PSA testing to improve cost-effectiveness and diagnostic accuracy.
  • To investigate methods for reducing unnecessary prostate biopsies through refined PSA analysis.

Main Methods:

  • Review of population-based studies on PSA screening and prostate cancer mortality.
  • Analysis of proposed adjustments to PSA testing protocols, including lower cut-off values (e.g., 2.5 ng/ml).

Related Experiment Videos

  • Examination of the role of different PSA derivatives and forms in diagnostic decision-making.

    • Main Results:

    • PSA screening is associated with reduced prostate cancer mortality.
    • Lowering PSA cut-offs may decrease the incidence of advanced-stage prostate cancer.
    • Utilizing various PSA forms could potentially reduce the number of 'unnecessary' biopsies.

    Conclusions:

    • Serum PSA is an indispensable tool in contemporary prostate cancer diagnosis and treatment.
    • Personalized screening strategies and refined PSA analysis hold promise for enhancing clinical outcomes.
    • Further research into PSA derivatives and optimized cut-offs may improve the specificity and efficiency of prostate cancer detection.